United States Drug Patent 6,977,253: Claim Scope, Expiration, Orange Book Status and Carbamazepine Patent Landscape

U.S. Patent No. 6,977,253 protects titration methods for treating bipolar disorder with extended-release carbamazepine. Its core subject matter is not the carbamazepine molecule or a particular tablet formulation. It is the clinical dosing sequence: beginning at a defined daily dose, increasing the dose in daily increments, and reaching efficacy or a final dose range.

The patent’s practical value was strongest against use of extended-release carbamazepine in bipolar mania or mixed episodes. Its U.S. patent term expired in 2022, eliminating current U.S. patent exclusivity from this patent. The claims remain relevant to historical litigation, patent-term analysis, and the scope of any claim that was asserted before expiration.

What does U.S. Patent 6,977,253 protect?

The patent protects methods of treating bipolar disorder using extended-release carbamazepine with accelerated titration.

The principal claim elements are:

Claim element	Scope
Patient population	Patient suffering from bipolar disorder
Active ingredient	Carbamazepine
Dosage form	Extended-release form
Initial daily dose	100 to 800 mg in the broad claims
Titration increment	100 to 400 mg per day in claims 1 and 2
Titration frequency	Daily increments
Treatment endpoint	Clinical efficacy or a specified final daily dose
Administration frequency	Twice daily in selected dependent claims
Final dose	1,000 to 1,600 mg in claim 19
Treatment subtypes	Manic episodes and mixed episodes
Combination therapy	Lithium, valproate, chlorpromazine, olanzapine, lamotrigine, gabapentin, or combinations

The patent is therefore a method-of-use patent with dosing-regimen limitations. It does not claim:

Carbamazepine as a chemical compound;
Extended-release carbamazepine as a composition in the abstract;
A specific polymer, coating, particle-size distribution, or release profile;
A manufacturing process;
A particular capsule or tablet strength;
Bipolar disorder treatment without the claimed titration sequence.

The claims can read on different extended-release carbamazepine products if the product is administered according to the claimed regimen.

Which claims are independent in U.S. Patent 6,977,253?

Claims 1, 2 and 19 are the principal independent claims.

Claim 1: accelerated titration with a side-effect limitation

Claim 1 requires:

Bipolar disorder treatment;
Extended-release carbamazepine;
An initial daily dose of 100 to 800 mg;
Daily dose increases of 100 to 400 mg;
Increases until clinical efficacy is achieved; and
Adverse effects no greater than those occurring with weekly dose increases.

The final limitation narrows claim 1 materially. It introduces a comparison against weekly titration. In a dispute, the patentee would likely need clinical, prescribing, or other evidence showing that the accused regimen satisfies the adverse-effect comparison.

This limitation also creates potential claim-construction issues. “Not greater than” requires a comparison, but the claim does not specify:

The patient population used for comparison;
The adverse events to be measured;
The observation period;
The statistical standard;
Whether the comparison must be based on clinical trial data or individual-patient experience.

Claim 1 is therefore narrower and potentially more evidentiary-intensive than claim 2.

Claim 2: the core accelerated-titration claim

Claim 2 removes the side-effect comparison and covers:

Bipolar disorder;
Extended-release carbamazepine;
An initial dose of 100 to 800 mg per day;
Daily increases of 100 to 400 mg;
Titration until clinical efficacy is achieved.

Claim 2 is the broadest practical claim in the patent because it does not require a specific final dose, administration frequency, bipolar subtype, concomitant drug, or demonstrated adverse-effect result.

Claim 19: final-dose regimen

Claim 19 requires:

An initial daily dose of 100 to 800 mg;
Daily increases;
A final daily dose of 1,000 to 1,600 mg.

Unlike claim 2, claim 19 does not expressly require the increments to be 100 to 400 mg. It does require daily increases and a final dose within the stated range.

The claim reaches the higher-dose titration strategy associated with acute treatment of mania or mixed episodes. Claims 20 through 28 narrow the initial or final dose ranges, including:

Initial dose of 100 to 400 mg;
Final dose of 1,200 to 1,600 mg;
Final dose of 1,200 to 1,400 mg;
Initial dose of 200 mg or 400 mg.

How do claims 3 through 18 narrow the patent?

Claims 3 through 18 depend from claim 2 or claim 1 and add clinical or dosing restrictions.

Claim	Added limitation
3	Patient suffers from manic episodes
4	Patient suffers from mixed episodes
5	Twice-daily administration
6	Initial dose is 200 mg
7	Initial dose is 400 mg
8	Initial dose is 600 mg
9	Initial dose is 800 mg
10	Daily increment is 100 mg
11	Daily increment is 200 mg
12	Daily increment is 300 mg
13	Daily increment is 400 mg
14	Concomitant lithium, valproate, chlorpromazine, olanzapine, lamotrigine, gabapentin, or combinations
15	Daily titration continues at least six days
16	Continue at the efficacious dose or reduce by daily increments while maintaining efficacy
17	Daily titration under claim 2 continues at least six days
18	Continued treatment or dose reduction after efficacy

Claims 6 through 13 are nested dose limitations. A regimen using a 400-mg initial dose and 200-mg daily increments can fall within multiple claims, including claims 2, 5, 7, 11 and potentially 17 or 18.

Claim 14 is narrower because it requires combination treatment. A generic manufacturer would not necessarily practice claim 14 merely by selling extended-release carbamazepine. The patient’s concomitant therapy and the prescriber’s instructions would matter.

Claims 16 and 18 extend beyond the titration phase. They cover maintaining the efficacious dose or reducing the dose by daily increments while retaining efficacy.

What do claims 29 through 34 add?

Claims 29 through 31 add a minimum titration period of five days to claims 1, 2 and 19. Claims 15 and 17 require at least six days. The five-day claims are broader in duration than the six-day claims.

Claims 32 through 34 specify a commercially important regimen:

Twice-daily administration;
Initial daily dose of 400 mg;
Daily increment of 200 mg.

The claims differ only in their dependency:

Claim 32 depends from claim 1;
Claim 33 depends from claim 2;
Claim 34 depends from claim 19.

Claim 32 retains claim 1’s side-effect comparison. Claim 33 does not. Claim 34 requires the final-dose framework of claim 19.

This 400-mg initial dose and 200-mg daily increment pattern corresponds closely to the dosing approach described in FDA labeling for Equetro, although the patent claims must be analyzed independently from the product label. [1]

What is the scope of “extended-release carbamazepine”?

The patent claims use “carbamazepine in extended release form” without limiting the claims to one named brand, capsule shell, excipient system, release mechanism, or manufacturing process.

The scope can therefore extend to:

Extended-release capsules;
Extended-release tablets;
Other orally administered extended-release dosage forms;

provided the dosage form and treatment regimen satisfy the claim language.

The patent does not necessarily cover immediate-release Tegretol or generic immediate-release carbamazepine when used under the claimed dosing schedule. The extended-release limitation is an express requirement in the principal claims.

Product-specific formulation patents could create a separate layer of protection. A formulation patent might claim release kinetics, multiparticulate beads, coating materials, excipient ratios, or capsule architecture. U.S. Patent 6,977,253 does not depend on those formulation features.

What was the relationship between the patent and Equetro?

Equetro is an extended-release carbamazepine product approved by the FDA for treatment of acute manic or mixed episodes associated with bipolar I disorder. The approved labeling describes twice-daily administration and dose escalation from an initial dose of 200 mg twice daily, with increases of 200 mg per day as clinically indicated. [1]

Those directions overlap materially with the narrower regimens in claims 5, 7, 11, 32, 33 and 34. The overlap explains the commercial relevance of the patent to Equetro and to generic or competing extended-release carbamazepine products.

The patent, however, is a method patent. FDA approval of a product does not by itself establish infringement. Infringement depends on whether the product is marketed, prescribed, or used in a manner meeting every limitation of an asserted claim.

When did U.S. Patent 6,977,253 lose exclusivity?

The patent’s U.S. term expired in November 2022, based on its earliest effective nonprovisional priority date and the standard 20-year term under 35 U.S.C. § 154. The patent therefore no longer blocks U.S. marketing of an otherwise approvable product or use regimen. [2]

Event	Approximate timing
Earliest priority basis	2001
U.S. application and examination	Early 2000s
Patent grant	December 20, 2005
U.S. patent expiration	November 2022
Current status	Expired by term

A patent-term adjustment or terminal-disclaimer analysis can affect the exact expiration date shown in official records. The operative business conclusion is unchanged: the patent is no longer an active U.S. barrier.

The patent is not a current source of U.S. patent exclusivity for Equetro or other extended-release carbamazepine products.

What was the Orange Book status of U.S. Patent 6,977,253?

The patent was associated with the regulatory exclusivity strategy for Equetro and was relevant to Orange Book-listed patent analysis during the product’s patent term. Orange Book-listed patents can support a Paragraph IV certification and associated Hatch-Waxman litigation while they remain listed and unexpired. [3]

After expiration, the patent no longer supports an enforceable future blocking position against an ANDA applicant. An applicant filing after expiration would not face the same litigation exposure based solely on this patent.

The listing also did not convert the patent into a product-composition patent. Its claim type remained a method-of-use patent. An ANDA applicant could address a method patent through a Paragraph IV certification, a section viii carve-out where legally available, or timing its approval and launch after expiration.

Were Paragraph IV challenges and litigation likely?

A Paragraph IV challenge would have targeted the patent before its 2022 expiration. The principal attack routes would have included:

Noninfringement because the proposed product is not labeled for the claimed titration method;
Invalidity for anticipation or obviousness;
Indefiniteness, particularly for “clinical efficacy” and the claim 1 adverse-effect comparison;
Lack of written description or enablement for the full dose and titration ranges;
Regulatory carve-out of the patented bipolar indication or dosing instructions.

The broadest litigation exposure centered on claim 2. A generic label that instructed treatment of bipolar disorder using extended-release carbamazepine, with a starting range of 100 to 800 mg and daily dose escalation, could create a stronger induced-infringement theory than a label omitting the patented indication or titration instructions.

Claims 1 and 19 present different vulnerabilities. Claim 1 has the additional side-effect comparison. Claim 19 requires a final dose of 1,000 to 1,600 mg. A product label that recommends a lower maximum dose, or does not instruct daily titration to that range, may avoid claim 19 even if it implicates claim 2.

No current enforcement risk remains from this patent after expiration. Historical litigation records should be checked through PACER and USPTO assignment and litigation databases before relying on a particular settlement date or consent judgment.

How strong was the patent estate?

The estate was moderate as a method-of-use portfolio but weaker as a standalone barrier after generic entry became possible.

Strengths

Broad claim 2 did not require a specific bipolar subtype.
The claims covered multiple starting doses and daily increments.
The claims reached both titration and maintenance or dose-reduction steps.
Claim 19 addressed the high-dose range used for acute manic or mixed episodes.
The regimen aligned with the approved use of Equetro.

Weaknesses

The claims required extended-release carbamazepine, limiting them to a dosage-form category.
“Clinical efficacy” is outcome-dependent and may complicate infringement proof.
Claim 1 requires a comparative adverse-effect showing.
Dose titration can be individualized in actual clinical practice.
Prior-art arguments could focus on known carbamazepine titration practices, bipolar treatment, and extended-release formulations.
The claims did not protect the active ingredient or a unique formulation.

The strongest historical claims were likely claims 2, 19, 33 and 34 when the product label expressly recommended the covered regimen. The strongest current commercial position is zero from this patent because the term has ended.

What other patents could affect generic entry?

A complete product-level freedom-to-operate review would distinguish five categories:

Patent category	Potential subject matter	Relevance after 2022
Method-of-use	Bipolar disorder dosing and titration	U.S. Patent 6,977,253 expired
Formulation	Extended-release matrix, beads, coatings, or release profile	Could remain relevant if separately unexpired
Manufacturing	Granulation, coating, encapsulation, or scale-up process	Could remain relevant
Labeling	Bipolar mania or mixed-episode indication	May be addressed through labeling strategy
Pediatric or regulatory exclusivity	FDA exclusivity attached to an NDA	Time-limited and separate from patent term

For carbamazepine, biosimilar risk is not applicable. Carbamazepine is a small-molecule active ingredient, not a biologic. The relevant competitive threats are ANDA-approved generics, authorized generics, branded extended-release products and formulation-specific competitors.

How does the patent compare with formulation patents?

U.S. Patent 6,977,253 is broader in clinical use but narrower in technology. It can cover different extended-release products if they are used under the claimed regimen. A formulation patent is narrower in product architecture but can block manufacture or sale of the dosage form regardless of the prescribing indication.

This distinction matters for generic strategy:

A generic could avoid the method patent through a label carve-out, if FDA and patent law permit;
It could not avoid a formulation patent merely by changing its label if the product itself practices the formulation claims;
After expiration of the method patent, remaining formulation or manufacturing patents would become the main patent barriers.

What generic launch scenarios exist now?

Because U.S. Patent 6,977,253 expired in 2022, the principal launch scenarios are:

Launch after approval if no other unexpired patent blocks the product;
Launch with a carved-out label if another method patent remains listed;
Launch under an authorized-generic arrangement;
Launch after resolving formulation or manufacturing patent disputes;
Compete with immediate-release carbamazepine while separately developing an extended-release product.

The expired patent no longer supports a 30-month stay for a new Paragraph IV challenge. Any current delay would have to arise from a different patent, regulatory exclusivity, FDA review issue, manufacturing problem, or commercial decision.

What licensing deals affected the patent?

The patent record itself establishes patent ownership and assignment, not the complete commercial licensing history. No license right can be inferred merely from the patent’s assignment data.

The commercially relevant rights were tied to the sponsor and approved product associated with Equetro. Any acquisition, supply, co-promotion, authorized-generic, or settlement agreement would require review of SEC filings, FDA records, court dockets and patent assignments. A patent assignment alone does not establish a license, royalty, field-of-use restriction or settlement.

Key Takeaways

U.S. Patent 6,977,253 is a method-of-treatment patent for bipolar disorder using extended-release carbamazepine.
Its central claim is daily titration from an initial dose of 100 to 800 mg until clinical efficacy.
Claim 19 separately covers daily escalation to a final dose of 1,000 to 1,600 mg.
Claims 32 through 34 focus on twice-daily dosing, a 400-mg initial daily dose and 200-mg daily increments.
The patent does not claim carbamazepine, a specific formulation, or a manufacturing process.
The patent expired in November 2022.
Paragraph IV and induced-infringement risk were historically most relevant to claims 2, 19, 33 and 34.
Biosimilar risk is not applicable because carbamazepine is a small-molecule drug.
Current U.S. entry risk depends on other formulation, manufacturing, method-of-use or regulatory barriers, not this patent.

FAQs

Does U.S. Patent 6,977,253 cover generic extended-release carbamazepine?

It covered certain methods of using extended-release carbamazepine for bipolar disorder during its term. It did not automatically cover every generic product or every use of the drug.

Could a generic avoid the patent by removing bipolar disorder from its label?

Before expiration, a label carve-out could have reduced infringement risk if the omitted indication or dosing instructions were the only basis for the patented use. The strategy would not necessarily avoid inducement based on other labeling, marketing or prescribing evidence.

Does the patent cover treatment of epilepsy with extended-release carbamazepine?

The claims supplied are directed to patients suffering from bipolar disorder. They do not expressly claim epilepsy treatment.

Is Equetro protected by a biologic exclusivity period?

No. Equetro contains carbamazepine, a small-molecule drug. Biologics Price Competition and Innovation Act exclusivity does not apply.

Can a new extended-release carbamazepine product still face patent risk after 2022?

Yes. The expired method patent is no longer a barrier, but separate formulation, manufacturing or later-filed method patents could affect launch timing if valid, enforceable and properly listed or asserted.

References

U.S. Food and Drug Administration. (2009). Equetro (carbamazepine) extended-release capsules prescribing information. FDA.
United States Patent and Trademark Office. (2005). U.S. Patent No. 6,977,253, Method for treating bipolar disorder. U.S. Department of Commerce.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
Patent Act, 35 U.S.C. § 154 (2024).
Drug Price Competition and Patent Term Restoration Act, 21 U.S.C. § 355(j) (2024).

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2452588	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 6,977,253

Summary for Patent: 6,977,253